Apixaban Degradation Impurities: New Inductee in Karpschem Impurities Portfolio

Apixaban Degradation Impurities: These are impurities that form as a result of the chemical degradation of Apixaban under certain conditions such as exposure to heat, light, or other environmental factors. Process Impurities: These impurities arise from the manufacturing process of Apixaban itself. They can include residual solvents, reagents, or by-products from synthesis. Potential Impurities: This […]

... Read More.

Clonidine Impurities Now Available Ready Stock in KarpsChem

Impurities are unwanted substances that may be present in clonidine drugs. Impurities can affect the quality, safety, and efficacy of the medication, and therefore must be carefully controlled and monitored. The presence of impurities can also impact the shelf-life and stability of the drug. It is important to consider the potential risks associated with impurities […]

... Read More.

Avail 10% Discount on In-stock Standards Now

In recent times, Fexofenadine Impurity synthesis was main objective for KarpsChem team. As we knowFexofenadine, α, α-dimethyl-4-[1-hydroxy-4-[4-(hydroxydiphenyl-methyl)-1-piperidinyl] butyl]-benzene acetic acid  is the active carboxylic acid analogue of the antihistamine terfenadine. It shares the histamine H1 receptor antagonist and non-sedative properties of the parent compound. This could be attributed to its capability to exist in zwitter-ionic […]

... Read More.

Now Brexpiprazole Impurities Available Ready Stock in KarpsChem

Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and major depressive disorders. Brexpiprazole has been associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.  Karpschem reference standards serves as basis for evaluation of both process and product performance and serves […]

... Read More.

Teneligliptin Impurities Now Available Ready Stock in KarpsChem

Teneligliptin hydrobromide hydrate was approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on June 29, 2012. It was co-developed & co-marketed as Tenelia® by Mitsubishi Tanabe and Daiichi Sankyo. Teneligliptin hydrobromide hydrate is a dipeptidyl peptidase-4 inhibitor. It is indicated for the treatment of type 2 diabetes. Tenelia® is available as tablet for oral use, […]

... Read More.

KarpsChem Recent Impurity Development Update: October

Variety of impurities like Genotoxic, Neurotoxic impurities required for agencies like USFDA, MHRDA etc,are available. KarpsChem specialized in manufacturing and supply of pharmacopoeia impurities, process impurities, isolation and identification of unknown impurities.

... Read More.